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2ABSTRACT15
Objectives: To elucidate the relationship of hCG administration to glycemia, Non16
Esterified Fatty Acids (NEFA), leptin and adiponectin levels on experimental animals17
previously submitted to a cafeteria diet, and then to a Low Calorie Diet (LCD). Design:18
Forty-one rats were selected (21 females, 20 males) and divided into seven (0-6) groups.19
Animals from groups 1 to 6 were fed a “cafeteria diet” with a mean energy content of20
10% protein, 30% carbohydrate and 60% fat. Animals from group 0 were fed the21
standard laboratory diet. After the fattening period, animals from groups 1 to 6 were22
submitted to a restricted diet consisting of one-third the average daily intake for rats. hCG23
was administered for five weeks according to a specific protocol. The effects of hCG24
treatment were evaluated using analysis of variance (ANOVA). Results: These25
assessments were compared: (1) glycemia, adiponectins, leptins and non-esterified fatty26
acids (NEFA); (2) weight; (3) formulation effect; and (4) dose effect. Differences in27
leptins were observed between the Control group and Injectable A (p=0.026), Intrarectal28
Suspension A (p=0.20), Intrarectal Suspension B (p<0.001), and Intrarectal Suspension C29
(p<0001) groups. In all cases, the average values were higher for the control group.30
Significant differences were found in the groups treated with Injectable B, Intrarectal31
Suspension B (p=0.025) and Intrarectal Suspension C (p=0.037). Groups receiving32
Intrarectal Suspension B or C showed significantly lower mean leptin values. Differences33
in glycemia were detected between the Control group and Intrarectal Suspension A34
(p=0.021) and Intrarectal Suspension B (p=0.020) groups. Groups treated with Intrarectal35
Suspension A or B showed lower mean blood glucose values. Conclusions: Results show36
the activity of hCG (both urinary and recombinant) on glycemia and leptins levels in37
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3experimental animals in different formulations, but specifically when administered38
intrarectal. hCG administration significantly decreased blood sugar and leptin levels,39
whereas adiponectins were only relatively sensitive to hCG treatment.40
Keywords: Human chorionic gonadotropin (hCG); Leptins; Glycemia; Adiponectin.41
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
11
.5
78
1.
1 
: P
os
te
d 
15
 M
ar
 2
01
1
4INTRODUCTION42
Human chorionic gonadotropin (hCG) was discovered in 1927 by Ascheim and Zondek43
in the urine of pregnant women and was used for the treatment of conditions such as44
infertility, cryptorchidism, and obesity 1-3. Several extragonadal therapeutic actions have45
been attributed to hCG, including (but not limited to) Kaposi sarcoma, glaucoma and46
BPH (Benign Prostatic hypertrophy). One of the most controversial indications was its47
use in the management of obesity, until a series of double blind studies conducted in48
humans concluded that weight loss under hCG was no better than placebo. The standard49
administration route was intramuscular. Its efficacy in obesity treatment was debated for50
years until some studies found it was not useful for treating this condition 4-8. In 1987,51
Vogt and Belluscio published a study concluding the hCG protocol originally designed52
by Simeons 3 for obesity treatment was a suitable and safe approach to manage this53
condition 9. The authors also reasserted the role of the hypothalamus as a possible54
intermediate organ for the lipolytic action of hCG 9.55
In 1999, Belluscio et al. worked on a modification of the hCG administration route as a56
strategy to modify its biological activity. They investigated the sublingual route,57
proposed a change in the administered dose, and in a double-blind study demonstrated the58
pharmacological activity of hCG in the reduction of adipose tissue total mass in volunteer59
subjects 10 11.60
Leptin was discovered in rats in 1994. Subsequently, the human Ob gene was located on61
chromosome 7. It is a cytokine that plays a key role in the regulation of energy balance. It62
is believed to act as a lipostate: when the amount of fat stored in adipocytes increases,63
leptin is released into the bloodstream and results in a negative feedback signal that acts64
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5on the hypothalamus to inhibit appetite. When adipose tissue mass increases beyond the65
point of equilibrium, the synthesis and secretion of leptin increases. This, in turn,66
stimulates several compensatory effects in the hypothalamus such as: anorectic peptide67
production and suppression of orexigenics, increase of energy expenditure, increase of68
basal metabolic rate and body temperature, and modification of the hormonal balance69
point, thereby reducing lipogenesis and increasing lipolysis 12-19. The regulation of leptin70
secretion is associated with variations in body mass and insulin-stimulating effects.71
However, many obese people have high serum concentrations of leptin or resistance to it,72
indicating that other molecules such as ghrelin, serotonin, cholecystokinin and73
neuropeptide Y also have an effect on satiety and contribute to body weight regulation 20-74
25. The molecular basis of leptin resistance is poorly understood; although the most75
accepted hypothesis is its inability to cross the blood brain barrier or the result of defects76
in the leptin receptor 26.77
Adiponectin is a peptidic hormone abundantly expressed in mature adipocytes that78
circulate in high concentrations in plasma. Adiponectin expression decreases in all79
processes related to inflammation and insulin resistance such as obesity and diabetes80
mellitus. Plasma adiponectin decreases before the onset of obesity and insulin resistance81
in primates, suggesting that hypoadiponectinemia contributes to the pathogenesis of these82
diseases. Adiponectin levels increase when insulin sensitivity improves, either due to the83
reduction in body weight or to treatment with insulin sensitizing drugs 27.84
The purpose of this study was to determine by plasma biochemistry analysis the85
metabolic activity of different hCG formulations, either urinary or recombinant, as well86
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6as its relationship to glucose, NEFA, adiponectin and leptin metabolism, and to assess its87
safety (particularly gonadal) through histological observations of target organs.88
89
SUBJECTS AND METHODS90
The study was conducted between December 12, 2008 and June 15, 2009 at the BIO91
FUCAL S.A. Center located at Acceso Norte km. 42.5, Del Viso, Buenos Aires,92
Argentina, and sponsored by Daniel Belluscio MD. Forty-one rats (Rattus norvegicus,93
Sprague Dawley strain) were selected comprised of 21 females and 20 males and divided94
in seven (0-6) groups. Animals in groups 1 to 6 were fed a hypercaloric and highly95
palatable cafeteria diet 28, in contrast to animals from group 0, which continued with the96
standard laboratory diet. The amount of food provided with this diet was “ad libitum” and97
extended from December 12, 2008 (day 0 of treatment) to January 27, 2009. After the98
fattening period, animals in groups 1 to 6 were subjected to a restricted diet consisting of99
one-third of the average daily intake of balanced food for rats, calculated separately for100
both males and females.101
hCG administration lasting five weeks was performed according to the following102
protocol. Group 0 received no medication or diet and continued with the standard diet103
throughout the course of the study. Group 1 was submitted to a hypocaloric diet without104
hCG administration. Group 2 was submitted to a hypocaloric diet and received 125105
International Units (IU) of hCG (urinary, Massone Laboratories, Buenos Aires,106
Argentina) dissolved in normal saline (NaCl 0.9%), administered intramuscularly and107
daily, including Sundays (Injectable A). Group 3 was submitted to a hypocaloric diet and108
received 125 IU of r-hCG (recombinant, Ovidrel®, Serono Laboratories, Buenos Aires,109
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7Argentina) dissolved in normal saline (0.9% NaCl), administered intramuscularly and110
daily, including Sundays (Injectable B). Group 4 was submitted to a hypocaloric diet and111
received 300 IU of hCG (urinary, Massone Laboratories, Argentina) in intrarectal112
emulsion containing 8 mg/ml of cyclodextrin (Laboratory Roquette Freres, Lestrem,113
France) as enhancer, daily, including Sundays (Intrarectal Suspension A). Group 5 was114
submitted to a hypocaloric diet and received 300 IU of hCG (urinary, Massone115
Laboratories, Argentina) in intrarectal emulsion containing 16 mg/ml of cyclodextrin116
(Laboratory Roquette Freres, France) as enhancer, daily, including Sundays (Intrarectal117
suspension B). Group 6 was submitted to a hypocaloric diet and received 300 IU of r-118
hCG (recombinant, Ovidrel®, Serono Laboratories) as intrarectal emulsion containing 8119
mg/ml of cyclodextrin (Laboratory Roquette Freres, France) as enhancer, daily, including120
Sundays (Intrarectal Suspension C).121
Injections were administered using 1 ml syringes and 16 x 5needles to the rear limbs122
between the semimembranosus and semitendinosus muscles, alternating one member per123
day. For intrarectal administration of the suspensions, the same syringes were used124
attached to an oesophageal probe for oral administration. The emulsion was deposited125
over the entire rectal surface, proximal to distal, keeping the anus closed for 1 minute.126
Both suspensions and injections were renewed every week and kept refrigerated at all127
times to ensure their biological activity.128
Observations were systematically recorded on each treated animal once a day throughout129
the duration of the trial. Body weight was assessed on days 0, 3, 6, 14, 21, 25, 33, 39130
(beginning of the treatment), 46, 53, 63, 77 and 82. The following serological131
determinations were assessed in each group at both baseline (day 39) and on the final day132
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8(82), pre- and post- treatment, respectively: Glycemia (g/L) (Colorimetric  end-point133
technique Autoanalyzer Hitachi 902 Wiener); adiponectin (ng/mL) (Rat adiponectin ELISA134
kit-ELISA manual- Catalog Nº K4903-100-Lot40203-Biovision Incorporated); leptin135
(ng/mL) (Mouse Leptin-Quantikine Immunoassay-ELISA-Lot 259828-Catalog Nr.136
MOBOO R&D Systems) and NEFA (mEq/L) (Mouse Non-ester Fatty Acid (NEFA)137
ELISA Kit  Product No.: CSB-E13618m-CUSABIO BIOTECH Co). Regarding the138
safety of hCG, histological evaluation of a general necropsy was performed. The139
following organs and tissues were removed to perform the pertinent histopathological140
studies: brain (half in buffered formaldehyde at 5% and half-frozen at -20° C), ovaries141
(formaldehyde 5%) and testicles (5% formalin).142
Statistical methodology143
The effects of hCG treatment were evaluated using analysis of variance (ANOVA). The144
Kolmogorov-Smirnov test was also used to assess normality of distributions.145
Nonparametric analysis of variance was used to compare weights between treatments at146
the beginning and end of treatment. Descriptive analysis of adverse events was147
performed. SPSS® software V. 11.5 (Cary, IN, USA) was used to assess the148
determinations.149
150
RESULTS151
We compared basal and final determinations as follows.152
General153
Basal determinations154
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9Figures 1 A-D show baseline results (before treatment) in the seven groups. To estimate155
their homogeneity, values were compared among the six groups submitted to high-calorie156
diets. No significant differences were found between groups: leptin (Fig. 1A), p=0.056;157
glycemia (Fig. 1B), p=0.291; adiponectin (Fig. 1C), p=0.364; and fatty acids (Fig. 1D),158
p=0.722.159
Final determinations160
Figures 2 A-D show final results (post treatment) in the seven groups. No significant161
differences were observed in adiponectin (F=2,130, p=0.076) (Fig. 2C) or fatty acids162
(F=1,056, p=0.408) (Fig. 2D), but statistically significant differences were observed in163
leptin (F=7,066, p<0.001) (Fig. 2A) and glucose (F=3,012, p=0.018) (Fig. 2B).164
Differences in leptin were observed between the Control group and the following groups:165
Injectable A (p=0.026), Intrarectal Suspension A (p=0.20), Intrarectal Suspension B166
(p<0.001) and Intrarectal Suspension C (p<0001). In all cases, the average values were167
higher for the Control group. Significant differences were also found in the group treated168
with Injectable B and in the Intrarectal Suspension B (p=0.025) and Intrarectal169
Suspension C (p=0.037) groups. Groups receiving Intrarectal Suspension B or C showed170
significantly lower mean leptin values. Differences in glycemia were detected between171
the Control group and the Intrarectal Suspension A (p=0.021) and Intrarectal Suspension172
B (p=0.020) groups. Groups treated with Intrarectal Suspension A or B showed lower173
mean blood glucose values.174
Treatment effect175
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10
Differences were first assessed between the Control group (Group 0), the group that was176
submitted to the hypocaloric diet (Group 1), and groups treated with hCG (Groups 2-6)177
(treatment effect).178
Leptin179
Significant differences were found in leptins among the treatments groups (F=9,694,180
p<0.001). The average value in the Control group was 3.05, 1.92 in the group treated only181
with hypocaloric diet, and 1.12 in groups treated with hCG. The most significant182
differences were found between the Control group and groups treated with hCG183
(p<0,001), while no significant differences were found between the two groups that did184
not receive hCG.185
Glycemia186
Significant differences were also observed in plasmatic glucose final values (F=8,099,187
p=0,001). The average value in the Control group was 1.78, 1.23 in the group treated188
with hypocaloric diet, and 1.15 in the groups treated with hCG. This difference is189
significant when comparing the Control group to the groups treated with hCG (p=0,001).190
Even though adiponectin plasmatic results were higher in the groups treated with hCG,191
differences were not statistically significant (F=1,388, p=0.262). The average value in the192
Control group was 2.69, 4.12 in the group treated with hypocaloric diet, and 5.80 in the193
groups treated with hCG. Statistically significant differences were not found in fatty acids194
(F=0.763, p=0.473). The average value for the Control group was 0.97, 0.85 in the195
hypocaloric diet group, and 0.90 in the groups treated with hCG.196
Dose effect197
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To assess the effect of the administered dose, groups were matched as follows: Control198
with standard diet, Control with hypocaloric diet, Injection A/Intrarectal Suspension A,199
Injectable B / Intrarectal Suspension C, Intrarectal Suspension B.200
Leptin201
Significant differences in leptin were observed between the groups (Brown-Forsythe202
5.473; p=0.009). The highest average values were recorded in the group that received the203
standard diet (3.05). Values were lower (1.92) in the group treated with hypocaloric diet,204
and even lower in the groups receiving hCG. Among those groups, the lowest mean205
values were recorded in animals receiving Intrarectal Suspension B. Differences were206
significant between the Control group and the groups receiving Injectable A/Intrarectal207
Suspension A (1.28, p=0.010), groups that received Injectable B/ Intrarectal Suspension208
C (1.30, p=0.012), and groups that received Intrarectal Suspension B (0.47, p<0.001).209
Glycemia210
Significant differences were observed in blood glucose between groups (F=4,078,211
p=0.008). Animals from the Control group showed higher average blood glucose values212
(1.78). A reduction in average values was observed in the group treated with hypocaloric213
diet (1.23) and in all subjects receiving hCG. When comparing animals under treatment,214
the lowest mean average values were observed in those receiving Intrarectal Suspension215
B (0.90). Significant differences were observed between the Control group and the group216
receiving Injectable A/Intrarectal Suspension A (1.05, p=0.016), the group receiving217
Injectable B/Intrarectal Suspension C (1.05, p=0.018), and the group receiving Intrarectal218
Suspension B (p=0.009).219
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Formulation effect220
To estimate the effect of the administered formulation, groups were matched and221
analyzed as follows: Control with standard diet, Control with hypocaloric diet, subjects222
with Injectable A/Intrarectal Suspension, A/Intrarectal Suspension B, and subjects with223
Injectable B/Intrarectal Suspension C.224
Leptins225
Significant differences in leptin levels were observed between the groups (Brown-226
Forsythe 4978; p=0.020). The highest average values (3.05) were observed in the Control227
group with standard diet. Values were lower (1.92) in the Control group with hypocaloric228
diet and in the groups receiving hCG. When comparing groups, the lowest mean values229
(1.01) were observed in animals receiving Injectable A/Intrarectal Suspension230
A/Intrarectal Suspension B. Statistically significant differences were found when231
comparing the Control group with standard diet and animals receiving Injectable232
A/Intrarectal Suspension A/Intrarectal Suspension B (p=0,001) and Injectable233
B/Intrarectal Suspension C (1.30, p=0.009).234
Glycemia235
Significant differences were observed when comparing blood glucose levels between the236
groups (F=5.307, p=0.004). The highest average values (1.78) were detected in the237
Control group that received the standard diet, and values decreased in the Control group238
treated with the hypocaloric diet (1.23) and in groups receiving hCG (1.00 and 1.05,239
respectively). Differences were significant between the Control group with the standard240
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diet and the groups receiving Injectable A/Intrarectal Suspension A/Intrarectal241
Suspension B (p=0.003) and Injectable B/Intrarectal Suspension C (p=0.010).242
Pharmaceutical formulation effect243
To estimate the different effects of the pharmaceuticals formulations, groups were split as244
follows: Control group with standard diet, Control group with hypocaloric diet, a group245
with Injectable A/B and a group with Intrarectal suspension A/B/C.246
Leptin247
Significant differences were observed in leptins between groups (Brown-Forsythe 7.398;248
p=0.008). The highest average values (3.05) were recorded in the Control group with the249
standard diet. In the Control group with the hypocaloric diet, the observed value (1.92)250
was decreased and further reductions were observed in the groups receiving hCG. Among251
the groups receiving treatment, lower average values (0.75) were found in the intrarectal252
suspension A/B/C groups. Differences were significant between the Control group with253
standard diet, the group receiving Injectable A/B (1.72, p=0.041), and the group receiving254
Intrarectal suspension A/B/C (p <0.001). Differences were also significant between the255
groups with the hypocaloric diet and the Intrarectal suspension group (p=0.040), and the256
Injectable and Intrarectal suspension groups (p=0.034).257
Glycemia258
Significant differences were observed in blood glucose levels among the groups (Brown-259
Forsythe F=5,667, p=0.003). Animals with the standard diet showed higher average260
blood glucose values (1.78). Mean values dropped (1.23) in the group treated with261
hypocaloric diet and in all groups receiving hCG. Among the treated groups, the lowest262
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mean values (0.97) were found in those receiving intrarectal suspension A/B/C.263
Significant differences were found between the Control group with standard diet, groups264
receiving Injectable A/B (1.11, p=0.019), and groups that received the Intrarectal265
suspension A/B/C (p<0.001).266
Weight assessment267
Figure 3 shows modifications in the mean weight of the seven groups.268
Treatment effect269
Significant differences were found between the groups regarding weight modifications270
(F=13,254, p<0.001). The average percentage variation for the standard diet group was271
0.4% (CI 95%; 8.8, 9.6). Results for the group with the hypocaloric diet were -24.7% (CI272
95%; 29.9, 19.4) and for hCG-treated groups they were -16.8% (CI 95%; -20.3, -13.3).273
Differences were significant in all three comparisons: the Control group with standard274
diet vs. the hypocaloric diet group (p<0,001); the Control group with standard diet vs.275
hCG-treated groups (p<0,001); and the Control group with hypocaloric diet vs. hCG-276
treated groups (p<0.001).277
Dose effect278
To assess the effect of the administered dose, groups were matched as follows: the279
Control group with standard diet, the Control group with hypocaloric diet, the groups280
with Injectable A/Intrarectal Suspension A, Injectable B/ Intrarectal Suspension C, and281
Intrarectal Suspension B. Significant differences were observed in weight percent change282
among groups between day 39 (baseline; before treatment, after cafeteria diet) and day 82283
(Brown-Forsythe=10,394, p=0 <0.001). Significant differences were also observed when284
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comparing the Control group under the standard diet (average percentage variation 0.4;285
CI 95%; 8.8, 9.6) vs. the Control group with the hypocaloric diet (-24.7, CI 95% -29.9, -286
19.4) (p<0.001); vs. the Injectable A/Intrarectal Suspension A group (-18.1, CI 95% -287
25.1, -11.2) (p=0,001); and vs. the Injectable B / Intrarectal Suspension C group (-18.3,288
CI 95% -23.0, -13.7) (p=0,001). There was also a significant difference between the289
Control group with hypocaloric diet and the Intrarectal suspension B group (-8.7, CI290
95%;-16.7, -0.6) (p=0.037).291
Formulation effect292
To assess the effect of the administered formulation, groups were analyzed as follows:293
the Control group with standard diet, the Control group with hypocaloric diet, and the294
Injectable A/Intrarectal suspension A/ Intrarectal suspension B, Injectable B/ Intrarectal295
suspension C groups. Significant differences in average weight percentage variations296
were observed between day 39 (baseline) and day 82 between the groups (Brown-297
Forsythe=11.201; 0.4-8.8, 9.6 p=0<0.001). Significant differences appeared when298
comparing the Control group with the standard diet (average percentage variation 0.4; CI299
95% CI; -8.8, 9.6) vs. the Control group with hypocaloric diet (-24.7, CI 95%; -29.9, -300
19.4) (p<0.001); vs. the Injectable A/Intrarectal suspension A/Intrarectal suspension B301
group (-15.6, CI 95%; -21.2, -10.0) (p=0.004); and vs. the Injectable B/Intrarectal302
suspension C (-18.3, CI 95% -23.0, -13.7) (p=0,001) group.303
Histopathology304
Significant morphological changes are summarized in Tables 1, 2 and 3.305
306
DISCUSSION307
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Leptin plays a key role in the regulation of energy metabolism. In disorders such as308
overweight and obesity, it is often elevated in plasma, suggesting that resistance to its309
action results in an impairment of the regulation of adipose tissue metabolism. Weight310
gain also determines the presence of hyperglycaemia, a metabolic situation that clearly311
aggravates the underlying pathology (obesity). In this study, it was possible to observe312
relevant differences about the effects of leptins. While the Control group with the313
standard diet started the study with significantly lower mean values, the achieved314
reduction was significantly less. Significant reductions in leptins were observed in the315
Control group with hypocaloric diet and in the Injectable A and B groups. At the end of316
the study, leptin results continued to be significantly different among some groups. The317
Control group with the standard diet showed higher average values, while the Intrarectal318
suspension B and C groups showed the lowest values.319
In addition, significant differences were also observed in mean blood glucose results. The320
Control group with the standard diet achieved the highest average values; higher than321
those of the groups treated with intrarectal suspension A or B. The Control group with the322
standard diet showed mean leptin and blood glucose values significantly higher than the323
groups treated with hCG. Moreover, no significant differences were found between the324
values of the Control group that received a standard diet and the Control group with the325
hypocaloric diet.326
Adiponectins and fatty Acids are not very sensitive to treatment when evaluating327
different doses and formulations. However, it was observed that, in relation to328
adiponectin, its values were elevated in animals receiving the hypocaloric diet, and even329
more so in the groups treated with hCG. Leptin and glucose levels were sensitive to330
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treatment. Leptin levels were significantly higher in the Control group, were decreased in331
the hypocaloric diet group, and even more decreased in the animals that received hCG.332
When comparing analysis per dose, the group treated with intrarectal suspension B333
showed the lowest values: the Injectable A/Intrarectal suspension A/Intrarectal334
suspension B groups showed the lowest levels in the analysis of the formulation, and the335
Intrarectal suspension A/B/C groups showed the lowest levels in the analysis of the336
pharmaceutical form. It is emphasized that no significant differences were observed337
between the groups that did not receive hCG. A similar effect was observed regarding338
glycemia. Treated groups showed significantly lower mean values in animals treated with339
Intrarectal suspension B (per dose analysis), in the animals treated with Injectable340
A/Intrarectal suspension A/Intrarectal suspension B (in the analysis of formulation), and341
in the animals treated with Intrarectal Suspension A/B/C (in the analysis of342
pharmaceutical form).343
These results demonstrate the activity of hCG (both urinary and recombinant) on344
glycemia and leptins levels in different formulations, but especially when administered345
intrarectal. Similarly to human studies performed by one of the authors (DOB), this346
activity did not correlate with a greater weight loss when compared to a population347
submitted to a standard hypocaloric diet. This result could either be attributed to the small348
number of animals in each group or it may also indicate a possible hCG effect on body349
composition, thereby favouring an increase in the lean mass component without350
modifying the total body weight. In addition, no significant adverse clinical effects were351
observed with the suprapharmacological doses administered (up to 400 times the dose/kg352
of body weight administered in humans).353
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These findings confirm the results from former studies in humans that show that weight354
loss under hCG is no different when compared to placebo-treated individuals. However,355
according to the authors, this is the first report that shows that hCG has a definite action356
on leptins and blood sugar metabolism.357
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TABLES:434
Table 1. Adverse events in brain histopathology per group/sex435
Brain Histopathology Group/sex
Vascular congestion in meninges and parenchyma. Group 4: 1 female
Group 6: 1 female
Vascular congestion and erythrocyte extravasation in
meninges.
Group 5: 1 female
Focal points of RBC extravasation in parenchyma Group 0: 1 female
Marked vascular congestion in meninges Group 5: 1 female
Group 6: 1 female
436
Table 2. Adverse events in testicular histopathology per group.437
GroupsTesticular
histopathology. 0 1 2 3 4 5 6
Mild autolysis 2 2 3 2
Moderate autolysis 1 1 3 3 3 1
438
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Table 3. Adverse events in ovaries histopathology per group.439
GroupsOvary histopathology.
0 1 2 3 4 5 6
CL (Corpus Luteum) 1
Yellowish-brown pigmento
focal points. 1
Follicles in different maturation
stages 2 1 3 2 3 5 2
Corpus Luteum in different
maturation stages 1
Interstitial cell hyperplasia. 2
Interstitial cells hyperplasia and
hypertrophy. 1 1 3 2 3 3 3
Interstitial cells mild
hyperplasia. 2
Luteomas 1 1 3 2 3 3 3
Pigment in CL 1 1
Cysts 2 2 2
440
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FIGURES441
Figures 1(A—D).Mean baseline determinations per group442
Figure 1A. Mean leptin baseline levels per group443
444
Figure 1B. Mean blood glucose (glycemia) baseline levels per group445
446
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Figure 1C. Mean adiponectin baseline levels per group447
448
Figure 1D. Mean fatty acids baseline levels per group449
450
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Figures 2(A—D).Mean final determinations per group451
Figure 2A.Mean leptin final levels per group452
453
Figure 2B. Mean blood glucose (glycemia) final levels per group454
455
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Figure 2C.Mean adiponectin final levels per group456
457
Figure 2D.Mean fatty acids final levels per group458
459
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Figure 3. Body weight modifications per group460
461
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